Icosapent ethyl (IPE) 4 g/day may exert a beneficial ‘legacy’ effect on cardiovascular (CV) risk in highly adherent patients even when they stop treatment, according to a post hoc analysis of REDUCE-IT data presented by Professor Chris Packard from the University of Glasgow, UK.1
Educational partners and supporters
Financial support was provided as a GMG Knowledge Gap Grant from Pfizer Inc.
Financial support was provided as a GMG Knowledge Gap Grant from Pfizer Inc.
Financial support was provided as a GMG Knowledge Gap Grant from Pfizer Inc.
Financial support was provided as a GMG Knowledge Gap Grant from Pfizer Inc.
